Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians

In East Asians, the incidence of type 2 DM (T2DM) has increased as a result of major alterations in life. Cardiovascular problems are more likely in those with T2DM. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel insulin-independent antihyperglycemic drugs that limit renal glucose reabs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Afzal, Fahad A. Al-Abbasi, Muhammad Shahid Nadeem, Sultan Alshehri, Mohammed M. Ghoneim, Syed Sarim Imam, Waleed Hassan Almalki, Imran Kazmi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cardioprotection East Asians diabetes mellitus SGLT2 inhibitors insulin independent Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/32e0385b14c4407eafcf06303044f11d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32e0385b14c4407eafcf06303044f11d
record_format	dspace
spelling	oai:doaj.org-article:32e0385b14c4407eafcf06303044f11d2021-11-25T18:20:58ZSodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians10.3390/metabo111107942218-1989https://doaj.org/article/32e0385b14c4407eafcf06303044f11d2021-11-01T00:00:00Zhttps://www.mdpi.com/2218-1989/11/11/794https://doaj.org/toc/2218-1989In East Asians, the incidence of type 2 DM (T2DM) has increased as a result of major alterations in life. Cardiovascular problems are more likely in those with T2DM. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel insulin-independent antihyperglycemic drugs that limit renal glucose reabsorption and thereby improve glycemic control. They are used alone or in combination with insulin and other antihyperglycemic medications to treat diabetes, and they are also helpful in protecting against the progression of complications. This review has evaluated the available evidence not only on the efficacy of SGLT2 inhibitors in T2DM, but also on their favourable cardiovascular events in East Asians. DM is an independent risk factor for cardiovascular diseases. As a result, in addition to glycemic control in diabetes management, the therapeutic goal in East Asian diabetic patients should be to improve adverse cardiovascular outcomes. Besides establishing antidiabetic effects, several studies have reported cardioprotective benefits of SGLT2 inhibitors via numerous pathways. SGLT2 inhibitors show promising antidiabetic drugs with potential cardiovascular advantages, given that a high number of diabetic patients in East Asia have co-existing cardiovascular disorders. Despite significant positive results in favour of SGLT2, more research is needed to determine how SGLT2 inhibitors exert these impressive cardiovascular effects.Muhammad AfzalFahad A. Al-AbbasiMuhammad Shahid NadeemSultan AlshehriMohammed M. GhoneimSyed Sarim ImamWaleed Hassan AlmalkiImran KazmiMDPI AGarticlecardioprotectionEast Asiansdiabetes mellitusSGLT2 inhibitorsinsulin independentMicrobiologyQR1-502ENMetabolites, Vol 11, Iss 794, p 794 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardioprotection East Asians diabetes mellitus SGLT2 inhibitors insulin independent Microbiology QR1-502
spellingShingle	cardioprotection East Asians diabetes mellitus SGLT2 inhibitors insulin independent Microbiology QR1-502 Muhammad Afzal Fahad A. Al-Abbasi Muhammad Shahid Nadeem Sultan Alshehri Mohammed M. Ghoneim Syed Sarim Imam Waleed Hassan Almalki Imran Kazmi Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
description	In East Asians, the incidence of type 2 DM (T2DM) has increased as a result of major alterations in life. Cardiovascular problems are more likely in those with T2DM. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel insulin-independent antihyperglycemic drugs that limit renal glucose reabsorption and thereby improve glycemic control. They are used alone or in combination with insulin and other antihyperglycemic medications to treat diabetes, and they are also helpful in protecting against the progression of complications. This review has evaluated the available evidence not only on the efficacy of SGLT2 inhibitors in T2DM, but also on their favourable cardiovascular events in East Asians. DM is an independent risk factor for cardiovascular diseases. As a result, in addition to glycemic control in diabetes management, the therapeutic goal in East Asian diabetic patients should be to improve adverse cardiovascular outcomes. Besides establishing antidiabetic effects, several studies have reported cardioprotective benefits of SGLT2 inhibitors via numerous pathways. SGLT2 inhibitors show promising antidiabetic drugs with potential cardiovascular advantages, given that a high number of diabetic patients in East Asia have co-existing cardiovascular disorders. Despite significant positive results in favour of SGLT2, more research is needed to determine how SGLT2 inhibitors exert these impressive cardiovascular effects.
format	article
author	Muhammad Afzal Fahad A. Al-Abbasi Muhammad Shahid Nadeem Sultan Alshehri Mohammed M. Ghoneim Syed Sarim Imam Waleed Hassan Almalki Imran Kazmi
author_facet	Muhammad Afzal Fahad A. Al-Abbasi Muhammad Shahid Nadeem Sultan Alshehri Mohammed M. Ghoneim Syed Sarim Imam Waleed Hassan Almalki Imran Kazmi
author_sort	Muhammad Afzal
title	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
title_short	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
title_full	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
title_fullStr	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
title_full_unstemmed	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
title_sort	sodium-glucose cotransporter-2 inhibitors improve cardiovascular dysfunction in type 2 diabetic east asians
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/32e0385b14c4407eafcf06303044f11d
work_keys_str_mv	AT muhammadafzal sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT fahadaalabbasi sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT muhammadshahidnadeem sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT sultanalshehri sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT mohammedmghoneim sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT syedsarimimam sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT waleedhassanalmalki sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians AT imrankazmi sodiumglucosecotransporter2inhibitorsimprovecardiovasculardysfunctionintype2diabeticeastasians
_version_	1718411310770683904

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians

Ejemplares similares